SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 268.35 |
| Enterprise Value ($M) | 193.09 |
| Book Value ($M) | 69.83 |
| Book Value / Share | 0.79 |
| Price / Book | 3.84 |
| NCAV ($M) | 57.97 |
| NCAV / Share | 0.65 |
| Price / NCAV | 4.63 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.77 |
| Return on Assets (ROA) | -0.57 |
| Return on Equity (ROE) | -0.76 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.68 |
| Current Ratio | 5.68 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 84.97 |
| Assets | 96.83 |
| Liabilities | 27.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.23 |
| Operating Income | -67.91 |
| Net Income | -64.02 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -69.12 |
| Cash from Investing | 17.23 |
| Cash from Financing | 39.86 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Federated Hermes, Inc. | 17.47 | 0.00 | |
| 13G/A | Logos Global Management LP | 2.10 | -69.83 | |
| 13G | Point72 Asset Management, L.P. | 6.20 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 137,643 | 695,265 | 19.80 | |
| 333,253 | 859,898 | 38.75 | |
| 310,816 | 787,698 | 39.46 | |
| 251,997 | 675,734 | 37.29 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ATHA – Athira Pharma, Inc. | ATNF – 180 Life Sciences Corp. |
| ATOS – Atossa Therapeutics, Inc. | AVTX – Avalo Therapeutics, Inc. |
| AYTU – Aytu BioPharma, Inc. |
Financial data and stock pages provided by
Fintel.io